ACHN
$6.25
Achillion Pharmaceuticals
($.09)
(1.42%)
ACHN
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.16)
Revenue:  N/A
Thursday
Feb 6
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ACHN reports earnings?
Beat
Meet
Miss

Where is ACHN's stock price going from here?
Up
Flat
Down
Stock chart of ACHN
Analysts
Summary of analysts' recommendations for ACHN
Score
Grade
Pivots
Resistance
$6.50
$6.45
$6.35

$6.29

Support
$6.19
$6.14
$6.04
Tweet
Growth
Description
ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease -- HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsCelgeneInterCeptJohnson & JohnsonMylanZoetisEndo International plcUltragenyx Pharmaceutical